Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Online ahead of print]

Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults

Affiliations

Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults

Kao-Ping Chua et al. JAMA Pediatr.

Abstract

Importance: Safe opioid prescribing practices are critical to mitigate the risk of prescription opioid overdose in adolescents and young adults. However, studies that examine opioid prescribing patterns associated with prescription opioid overdose have mostly focused on older adults. The generalizability of these studies to adolescents and young adults is unclear.

Objective: To identify opioid prescribing patterns associated with prescription opioid overdose in adolescents and young adults.

Design, setting, and participants: This retrospective cohort study assessed privately insured patients aged 12 to 21 years with opioid prescription claims in the IBM MarketScan Commercial Claims and Encounters database between July 1, 2009, and October 1, 2017, and no cancer diagnosis. Data analysis was performed from January 1 to April 30, 2019.

Main outcomes and measures: The outcome was a treated opioid overdose as indicated by diagnosis codes. On the basis of days supplied, opioid prescription claims were converted to person-days (the unit of analysis) on which opioid exposure would occur if patients took medications as prescribed. Logistic regression with clustered SEs at the patient level was used to model the occurrence of overdose on a person-day as a function of daily opioid dosage category (<30, 30-59, 60-89, 90-119, or ≥120 morphine milligram equivalents), concurrent benzodiazepine use, and extended-release or long-acting opioid use. Regressions controlled for demographic characteristics, year, opioid use within 180 days, and comorbidities (mental health disorder, substance use disorder, and other chronic condition).

Results: A total of 2 752 612 patients (mean [SD] age at cohort entry, 17.2 [2.5] years; 1 451 918 [52.8%] female) participated in the study. Patients had 4 686 355 opioid prescription claims, corresponding to 21 605 444 person-days. Overdose occurred on 255 person-days among 249 patients (0.01% of the sample). Each increase in daily opioid dosage category was associated with higher overdose risk (adjusted odds ratio [AOR], 1.18; 95% CI, 1.05-1.31). Compared with no use, both concurrent benzodiazepine use (AOR, 1.83; 95% CI, 1.24-2.71) and extended-release or long-acting opioid use (AOR, 2.01; 95% CI, 1.16-3.46) were associated with increased overdose risk.

Conclusions and relevance: The findings suggest that when prescribing opioids to adolescents and young adults, practitioners could potentially mitigate overdose risk by using the lowest effective daily dosage, avoiding concurrent opioid and benzodiazepine prescribing, and relying on short-acting opioids. Findings are broadly consistent with prior opioid safety studies focused on older adults.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Chua reported receiving funding from career development award 1K08DA048110-01 from the National Institute on Drug Abuse. Dr Brummett reported working as a consultant for Heron Therapeutics during the conduct of the study and receiving funding from Recro Pharma Inc, the National Institutes of Health, the Michigan Department of Health and Human Services, National Institute on Drug Abuse, and the UM Michigan Genomics Initiative outside the submitted work. In addition, Dr Brummett had a patent to peripheral perineural dexmedetomidine issued and licensed. No other disclosures were reported.

Comment in

  • JAMA Pediatr. doi: 10.1001/jamapediatrics.2019.4885

Similar articles

See all similar articles

LinkOut - more resources

Feedback